Pancreastatin NYS DOH Approved tests PFI#9065

ISI Order Code:

PST

CPT Code:

83519

Clinical Significance:

Pancreastatin is a 49 amino acid peptide produced by degradation of Chromo-granin A.  It inhibits Chromogranin A and Parathyroid Hormone release.  Pancreastatin also inhibits release of Somatostatin upon glucose stimulation.  It may also control carbohydrate metabolism and hyperglycemia.  Although there are no compounds with significant structural homology with Pancreastatin, there are minor similarities to Gastrin and Anti-Diuretic Hormone.  Pancreastatin reduces the the early phase of Glucose induced Insulin release.  Suppression of Insulin release upon Glucose stimulation is a characteristic feature of Type II Diabetes.  Pancreastatin could play an important therapeutic role in the treatment of diabetes.  Pancreastatin also inhibits release of Somatostatin.  It may also control carbohydrate metabolism and hyperglycemia. The ISI plasma Pancreastatin test is NY approved and has been part of several publication and clinical studies.

Reference Range:

10 – 135 pg/ml

Procedure:

Pancreastatin is measured by direct radioimmunoassay.

Expected Turnaround Time: 

3-5 Business Days

Turnaround time is defined as the usual number of days from the date of receipt of a specimen for testing to when the result is released to the ordering provider. Testing schedules may vary.

Report:

Sample Report

Patient Preparation:

Patient should be fasting 10-12 hours prior to collection. Patient should not be on any medications that may influence Insulin levels, if possible, for at least 48 hours prior to collection.

Specimen Collection:

Collect 10mL blood directly into ISI’s Z-tube^TM Preservative and separate as soon as possible. Freeze plasma immediately after separation. Special Z-tube^TM Preservatives are available from ISI. Minimum specimen size is 1mL.

Note: one Z-tube^TM may be shared for up to three tests (Pancreastatin, NKA, and 5HIAA). . After centrifuging tube, aliquot 1mL per test in separate vials, mark with name of test and freeze.

Please contact ISI for separation using a non refrigerated centrifuge. Contact ISI for details.

The Inter Science Institute Z-tube™ collection and preservative tube is intended  for use with Inter Science Institute’s 5-Hydroxyindoleacetic acid (5-HIAA), Neurokinin A (NKA), Neuropeptide Y (NPY), Neurotensin, Pancreastatin, and Substance P assays only. It has not been validated for use with other in vitro assays. Effects of using this device other than as intended are unknown, and is not recommended.

Important Precaution:

Specimens for this assay must be collected using the Z-tube^TM. Specimens must be shipped frozen; specimens are not stable at refrigerated or room temperatures. No other specimens are acceptable.

Rejection Criteria: 

Gross hemolysis/lipemia/icteric

Special Specimens:

For tumor/tissue and various fluids (i.e. CSF, peritoneal, synovial, etc.) contact the Institute for requirements and special handling.

Shipping Instructions:

Ship specimens frozen in dry ice.

References:

• 1. Raines D, Chester M, Diebold AE, et al. A prospective evaluation of the effect of chronic proton pump inhibitor use on plasma biomarker levels in humans. Pancreas. 2012;41(4):508-511.
• 2. O’Dorisio TM, Krutzik SR, Woltering EA, et al. Development of a highly sensitive and specific carboxy-terminal human Pancreastatin assay to monitor neuroendocrine tumor behavior. Pancreas. 2010;39(5):611-616.
• 3. Piero E, Mirelles P, Silvestre RA, et al. Pancreastatin inhibits insulin secretion as induced by glucagon, vasoactive intestinal polypeptide, gastric inhibiting peptide, and 8-cholecystokinin in the perfused rat pancreas. Metabolism. 1989;38:679-82.
• 4. Tatemoto K, Efendi S, Mutt S, et al. Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion. Nature. 1986;324:476-8.
• 5. Calhoun K, Toth-Fejel S, Chee J, et al. Serum peptide profiles in patients with carcinoid tumors. Am J Surg. 2003;186(1):28-31
• 6. Syversen U, Jacobsen MB, O’Connor DT, et al. Immunoassays for measurement of chromogranin A and pancreastatin-like immunoreactivity in humans: correspondence in patients with neuroendocrine neoplasia. Neuropeptides. 1994;26(3):201-6
• 7. Kogner P, Bjellerup P, Svensson T, et al. Pancreastatin immunoreactivity in favourable childhood neuroblastoma and ganglioneuroma. Eur J Cancer 1995;31A(4):557-60.
• 8. Desai DC, O’Dorisio TM, Schirmer WJ, et al. Serum pancreastatin levels predict response to hepatic artery chemoembolization and somatostatin analog therapy in metastatic neuroendocrine tumors. Regul Pept. 2001;96(3):113-17.